Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

Authors

Bernard Doger de Spéville

Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Madrid, Spain

Bernard Doger de Spéville , Enriqueta Felip , Martin Forster , Margarita Majem , Pawan Bajaj , Julio Antonio Peguero , Enric Carcereny , Matthew G Krebs , Uma Mukherjee , Christian Mueller , Frederic Triebel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

First Author: Enriqueta Felip

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

First Author: Julio Antonio Peguero

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

First Author: Igor Tsaur

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

First Author: Hsiang-fong Kao